Life Scientist > Biotechnology

The designer dairy cow

30 November, 2005 by Graeme O'Neill

Comparative genomics is helping speed up the identification of genes for desirable production traits in livestock, Graeme O'Neill reports.


Plants, proteins and proteomics

29 November, 2005 by Susan Williamson

Profiling proteins is a challenging undertaking. But new research is providing new insights into protein structure and function, reports Susan Williamson.


Positive results for Peplin phase IIa 'sun spot' trial

28 November, 2005 by Helen Schuller

Peplin (ASX:PEP) has reported positive results from its phase IIa clinical trial of its proprietary drug PEP005 Topical in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer.


US Army to participate in Neuren phase III trials

24 November, 2005 by Helen Schuller

Auckland biopharma Neuren Pharmaceuticals (ASX:NEU) has executed a memorandum of understanding (MOU) with the Henry M. Jackson Foundation for the Advancement of Military Medicine for inclusion of US Army hospital sites in Neuren's phase III trial of its lead drug Glypromate.


Probiomics to commence flu vaccine trial

24 November, 2005 by Ruth Beran

Probiomics' (ASX:PCC) shares increased by more than 25 per cent yesterday on news that the company will undertake a clinical trial to examine the ability of its proprietary probiotic strain PCC to boost the immune response to a vaccine for influenza.


Fast composter for city waste

23 November, 2005 by Graeme O'Neill

Researchers from the Environmental Biotechnology Cooperative Research Centre (EBCRC) have successfully tested a, self-sustaining process that rapidly composts municipal solid wastes.


Norwood commences phase II cancer vaccine trial

21 November, 2005 by Graeme O'Neill

Melbourne meditech Norwood Immunology (AIM:NIM) has recruited the first of 100 post-surgical melanoma patients into a phase II clinical trial of its thymus-rejuvenating technology, using the gonadotrophin releasing hormone (GNRH) analogue Lupron Depot.


National bioprospecting regulations released

21 November, 2005 by Ruth Beran

The Australian government has released new national environmental regulations to control 'bioprospecting' -- the search for new chemicals in living things that will have some medical or commercial use.


CSIRO abandons GM pea project

18 November, 2005 by Graeme O'Neill

CSIRO Plant Industry researchers have abandoned a project to develop a genetically modified field pea with resistance to the pea weevil, Bruchus pisorum.


Novogen pleased by cancer drug results

18 November, 2005 by Ruth Beran

Trials of Novogen's (ASX:NRT) anti-cancer drug phenoxodiol have shown it significantly delays tumour progression in men suffering from late-stage hormone refractory prostate cancer and produces anti-cancer responses in women with cervical cancer.


OPINION: Taking advantage of our clinical strengths

18 November, 2005 by Graeme Blackman

Australia, take a bow -- you've proved you can compete in the global clinical trials market. But let's not get too complacent, writes Graeme Blackman.


REPORT: How we score on pharma R&D

18 November, 2005 by Ruth Beran

Ruth Beran wraps up a recent report that gives Australia a high rating against other major centres of pharma R&D.


Aust CROs tell of boom in clinical trials work

18 November, 2005 by Ruth Beran

Ruth Beran spoke with Australian contract research organisations and found that there is strong demand for Australian clinical trials, both from within Australia and also from overseas.


New research shows Aussie lizard bites can really hurt

17 November, 2005 by Graeme O'Neill

Australian venom researchers have uncovered a 200-million year old secret: Australia's goannas and bearded dragons, Indonesia's giant Komodo dragon, and their iguana cousins, are more closely related to snakes than to other lizards -- and they're venomous.


Metabolic reports successful phase I trials

16 November, 2005 by Graeme O'Neill

Melbourne biopharma Metabolic (ASX:MBP) has announced plans to take its ACV1 conotoxin analgesic into phase IIa clinical trial in volunteers with chronic neuropathic pain next year.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd